Saniona, a clinical-stage biopharmaceutical company focused on rare diseases of the central nervous system, announced a new research and development collaboration with Boehringer Ingelheim focused on the identification of new treatment options for schizophrenia, by exploring a novel undisclosed CNS ion channel target.
Thus, Saniona and Boehringer Ingelheim have now two ongoing partnerships for the discovery and development of new small molecule therapeutics for patients with schizophrenia. Their first collaboration was initiated in 2016 and the first candidate for preclinical and clinical development was selected in July 2018.
